The Newsroom

Find out the latest about Calidi. Announcements, press coverage, publications, and company info—it’s all here.

Press Release

Join Calidi Biotherapeutics’ Exclusive Live Investor Webinar and Q&A Session on April 24

SAN DIEGO, April 22, 2025 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics Inc. (NYSE American: CLDI) (“Calidi”), a clinical-stage biotechnology company developing a new generation of targeted antitumor virotherapies, is pleased to invite investors to a webinar on April 24, 2025, at 4:15 p.m. ET.

The Newsroom

Join Calidi Biotherapeutics’ Exclusive Live Investor Webinar and Q&A Session on April 24

Calidi Biotherapeutics Announces The Appointment Of Seasoned Biotech Executive Dr. Ashok Srivastava To Their Scientific Advisory Board

Calidi Biotherapeutics Announces A Collaborative Study With The National Institutes Of Health (NIH) On The Therapeutic Potential Of Oncolytic Viruses Delivered By Mesenchymal Stem Cells

Calidi Biotherapeutics Releases Recent Interviews of CEO Allan Camaisa

Delivery of oncolytic vaccinia virus by matched allogeneic stem cells overcomes critical innate and adaptive immune barriers

Calidi Biotherapeutics Launches Scientific and Medical Advisory Board

Calidi Biotherapeutics, Inc. announces its corporate vision in groundbreaking cancer drug development and appoints Allan Camaisa as CEO

Calidi Biotherapeutics Announces Dr. Maciej S. Lesniak Presentation at 13th International Oncolytic Virotherapy Conference

Calidi Biotherapeutics Announces Presentation at 6th Annual Oncolytic Virotherapy Summit

Calidi Biotherapeutics Announces Exclusive License Agreement with City of Hope and the University of Chicago for Novel Oncolytic Virotherapy Technology

Calidi Biotherapeutics Announces Agreement with Northwestern University for Exclusive Commercial Rights to their IND for Treatment of Malignant Glioma

Calidi Biotherapeutics Announces Partnership with GenScript ProBio for Distribution of its SuperNova-1 Technology

Calidi Biotherapeutics Announces European Patent Granted by EPO: Combination Immunotherapy Approach for Treatment of Cancer

Rationale for the clinical use of adipose-derived mesenchymal stem cells for COVID-19 patients

ASCO-SITC Clinical Immuno-Oncology Symposium February 6-8, 2020 Orlando, Florida.

A cell-based platform to potentiate oncolytic virus: Potential approach for cancer therapies.

First-in-human study of TK-positive oncolytic vaccinia virus delivered by adipose stromal vascular fraction cells

First-in-human study of TK-positive oncolytic vaccinia virus delivered by adipose stromal vascular fraction cells

Delivery of oncolytic vaccinia virus by matched allogeneic stem cells overcomes critical innate and adaptive immune barriers

Scientific Advisory Board Member Interview - Santosh Kesari, M.D./Ph.D.

Scientific Advisory Board Member Interview - Bernard Fox, Ph.D.

Scientific Advisory Board Member Interview - W.K. Alfred Yung, M.D.

Scientific Advisory Board Member Interview - Ashok Srivastava, M.D./Ph.D.

Big Biz TV - Stephen Thesing

Big Biz TV - Allan Camaisa

Analyst Bullish On Calidi Biotherapeutics, Newly Listed Cancer Treatment Player

Calidi Biotherapeutics: A Promising Player in the Cancer Treatment Market

All Courses

A talented, seasoned group of world-class executives, doctors, and scientists producing revolutionary work.